Oruka Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
ORKA$104.56+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share data)
| December 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $46,935 | $61,575 |
| Marketable securities, current | 290,109 | 314,073 |
| Prepaid expenses and other current assets | 6,813 | 1,221 |
| Total current assets | 343,857 | 376,869 |
| Marketable securities, long-term | 142,539 | 18,069 |
| Property and equipment, net | 288 | 162 |
| Operating lease right-of-use assets | 1,830 | 876 |
| Other non-current assets | 103 | 43 |
| Total assets | $488,617 | $396,019 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $4,155 | $3,462 |
| Accrued expenses and other current liabilities | 10,591 | 3,346 |
| Operating lease liability, current | 619 | 213 |
| Related party accounts payable and other current liabilities | 9 | 6,022 |
| Total current liabilities | 15,374 | 13,043 |
| Operating lease liability, non-current | 1,313 | 755 |
| Total liabilities | 16,687 | 13,798 |
| Commitments and contingencies (Note 15) | ||
| Stockholders’ equity: | ||
| Series B non-voting convertible preferred stock, $0.001 par value; 251,504 shares authorized as of December 31, 2025 and 2024; 137,138 shares issued and outstanding as of December 31, 2025 and 2024 | 2,931 | 2,931 |
| Common stock, $0.001 par value as of December 31, 2025 and 2024; 545,000,000 shares authorized as of December 31, 2025 and 2024, 48,722,309 and 37,440,510 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 49 | 37 |
| Additional paid-in capital | 657,561 | 463,018 |
| Accumulated other comprehensive income (loss) | 546 | (41) |
| Accumulated deficit | (189,157) | (83,724) |
| Total stockholders’ equity | 471,930 | 382,221 |
| Total liabilities and stockholders’ equity | $488,617 | $396,019 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.